299. Cystic fibrosis Clinical trials / Disease details
Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01737983 (ClinicalTrials.gov) | May 2009 | 12/7/2012 | Effect of Lactobacillus Reuteri in Cystic Fibrosis | Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis. | CYSTIC FIBROSIS | Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: placebo | Azienda Policlinico Umberto I | NULL | Completed | 6 Years | 42 Years | Both | 61 | Phase 4 | Italy |